《大行報告》瑞銀下調敏華(01999.HK)目標價至12.5元 評級「買入」
瑞銀髮表評級報告指,於高基數的基礎下,敏華(01999.HK)在下半財年收入按年增15.2%至113億元,高於該行預期1.9%,低於市場預期0.8%;其經調整淨利潤爲13億元(按年增9.5%),分別高於該行預期6.3%及市場共識10.4%。
該行表示,管理層計劃今年於內地市場開設300至500間新店,對較低線城市的潛力維持正面態度。長遠而言,管理層預料其功能沙發市場規模至少擴大一倍。受新冠疫情對線下流量的影響,該行稍微將公司23/24財年收入預測下調2.8%及4.7%。
該行基於近期盈利修正,將其目標價由13元下調至12.5元,重申其評級爲「買入」。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.